News & Events
Clean Mails – December 2024
Clean Biologics' News:
Next-Generation Sequencing, Single Cell Cloning, Exosomes, HIV vaccine...
NEW:
Clean Cells expands its cGMP identity tests by integrating Next-Generation Sequencing !
Clean Cells, already known for its wide range of tests, continues to expand its offer by integrating Illumina® technology into its services, enabling high-throughput sequencing for identity purpose.
New single cell cloning services to accelerate cGMP cell banks production
As a contract organization specializing in cGMP cell & virus banking and Quality Control testing, Clean Cells knows the importance of qualitative cell line development.
We thus implemented a state-of-the-art single cell cloning platform to isolate potent clones and characterize the monoclonality of biotherapeutics producing cell lines.
Exosomes, Your new therapeutic vector
With the experience accumulated by the team for more than 20 years on viral-based products, Naobios perceives the development and manufacturing of exosomes as a natural extension of our capabilities.
It is thus our goal to expand activities in this field, sustained by our strict segregation policies and cleaning procedures.
Press Release:
Naobios and Sumagen successfully optimize HIV vaccine candidate for industrial production
Naobios and Sumagen Canada Inc, a Korean-Canadian biotechnology company, developing an HIV-1 vaccine candidate, today announce the production of the HIV-1 vaccine candidate at bench scale.
This key milestone puts Naobios in a position to scale up the production of Sumagen’s HIV-1 vaccine candidate following a partnership agreement signed in April 2024 to manage the manufacturing process. Naobios has achieved this within the initial schedule, bringing Sumagen closer to delivering its HIV vaccine candidate to the public. This was made possible through the Naobios’ site, which has the required BSL3 production capabilities for highly pathogenic viruses.